Scarica l'app Stockscreener
6.99
21.28%
-1.89
Dopo l'orario di chiusura:
6.95
-0.04
-0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Precedente Chiudi:
$8.88
Aprire:
$6.41
Volume 24 ore:
51.70M
Relative Volume:
10.63
Capitalizzazione di mercato:
$1.52B
Reddito:
$61.10M
Utile/perdita netta:
$-138.36M
Rapporto P/E:
-5.1778
EPS:
-1.35
Flusso di cassa netto:
$-90.59M
1 W Prestazione:
-22.59%
1M Prestazione:
-37.98%
6M Prestazione:
-44.61%
1 anno Prestazione:
-3.98%
Intervallo 1D:
$6.2301
$7.13
Intervallo di 1 settimana:
$6.2301
$9.34
Portata 52W:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
6.99 | 1.93B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.32 | 124.83B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
793.53 | 84.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
843.55 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.61 | 41.70B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.86 | 38.30B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-15 | Iniziato | Chardan Capital Markets | Buy |
| 2025-04-08 | Iniziato | William Blair | Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-11 | Iniziato | Needham | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test - MedCity News
Ocular Therapeutix Shares Fall After Eye Disease Treatment Shows Superiority in Phase 3 Trial at Week 36 - marketscreener.com
Ocular Therapeutix (OCUL) Shares Drop Amid Clinical Study Results - GuruFocus
Ocular: "Buy" As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk - Fierce Pharma
Ocular claims a win with eye drug data even as shares sink - BioPharma Dive
Ocular Therapeutix (OCUL) Stock Drops Following SOL-1 Trial Results - GuruFocus
Ocular Therapeutix releases positive topline results from SOL-1 - Ophthalmology Times
Ocular eyes superiority claim after Axpaxli success in wet AMD study, but shares fall - FirstWord Pharma
Ocular Therapeutix’s wet AMD treatment shows superiority over aflibercept - Investing.com Nigeria
Promising Biotech Ocular Gets Price Target Update After Groundbreaking Therapy News - TheStreet Pro
Ocular Therapeutix Shares Drop Following Axpaxli Trial Data Disappointment - Intellectia AI
Ocular Therapeutix Financial Results Disappoint Investors - StocksToTrade
Ocular Therapeutix Struggles After Missing Revenue Expectations - timothysykes.com
Ocular Therapeutix (OCUL) Drops 22% Despite Positive Trial Resul - GuruFocus
Ocular Therapeutix's AXPAXLI Meets Superiority Endpoint In Wet AMD Trial, But Stock Down - Nasdaq
Ocular drops after late-stage trial data for wet AMD therapy - Seeking Alpha
Ocular Therapeutix stock news: Why positive data led to a 25% drop - Investing.com Canada
Ocular Therapeutix (OCUL) Achieves Success in Phase 3 Trial for Wet AMD Treatment - GuruFocus
Ocular Therapeutix reports positive results from Sol-1 phase 3 superiority trial in wet AMD - marketscreener.com
Ocular Therapeutix stock tumbles after wet AMD trial results By Investing.com - Investing.com Canada
Ocular Therapeutix stock tumbles after wet AMD trial results - Investing.com UK
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial - TradingView
Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial - statnews.com
OCUL: AXPAXLI demonstrated statistically significant superiority to aflibercept in wet AMD at Week 52 - TradingView
Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD - GlobeNewswire
Ocular Therapeutix stock jumps in premarket as SOL-1 wet AMD data nears - Bez Kabli
OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds - Stocktwits
Deep Track Capital, LP Reduces Stake in Ocular Therapeutix Inc - GuruFocus
Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes - Bitget
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom - The Chronicle-Journal
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data - FinancialContent
Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - marketscreener.com
Ocular Therapeutix to Announce Topline Data from SOL-1 Phase 3 Trial for Wet AMD on February 17, 2026 - geneonline.com
Will Ocular Therapeutix Inc. benefit from geopolitical trendsTrade Risk Report & Long-Term Safe Investment Ideas - mfd.ru
Ocular Therapeutix to Host Webcast Presenting SOL-1 Data for AXPAXLI™ on February 17, 2026 - Quiver Quantitative
Ocular Therapeutix™ to Announce Topline Data for SOL-1 - GlobeNewswire
Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix Equity Grants Balance Growth Plans And Dilution Concerns - Yahoo Finance
Why It's Time To Keep A Close Eye On OCUL - RTTNews
Ocular Therapeutix (OCUL) Stock Analysis: A Biotech Gem With 171% Upside Potential - DirectorsTalk Interviews
How Investors Are Reacting To Ocular Therapeutix (OCUL) Revenue Miss And Widening 2025 Net Loss - Sahm
Bearish Setup: Is Ocular Therapeutix Inc gaining market shareDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
Ocular Therapeutix Faces Declining Sales and Profitability Amid Market Sentiment Shift - Markets Mojo
Aug Closing: Will Ocular Therapeutix Inc stock hit new highs in YEARMarket Sentiment Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL) - The Globe and Mail
Will Ocular Therapeutix Inc stock hit new highs in YEARWeekly Risk Summary & Safe Entry Point Identification - baoquankhu1.vn
Ocular Therapeutix (NASDAQ:OCUL) Raised to Hold at Wall Street Zen - MarketBeat
(OCUL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
RBC Capital reiterates Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):